由纤维素纳米纤维/乳清蛋白复合体稳定并用甲修饰的微囊:特征和释放特性
Dan Wang1, Lin Liu1, Tanghui Liu1
1School of Food and Bioengineering, Xihua University, Chengdu 610039, Sichuan, China.
Food chemistry
|January 29, 2025
概括
这项研究优化了Zanthoxylum schinifolium精油 (ZSEO) 微囊,使用细菌纤维素纳米纤维素/乳清蛋白分离物 (BCNFs/WPI) 和甲 (CA). 由此产生的微囊表现出增强的稳定性和受控释放,改善了ZSEO的输送.
科学领域:
- 食品科学与技术 食品科学与技术
- 材料科学 材料科学 材料科学
- 生物技术是生物技术.
背景情况:
- 精油 (EOs) 具有宝贵的特性,但容易降解和生物可用性较低.
- 微封装是保护EO和控制其释放的关键策略.
- 细菌纤维素纳米纤维素 (BCNF) 和乳清蛋白分离物 (WPI) 为封装提供了有前途的生物相容矩阵.
研究的目的:
- 为了优化Zanthoxylum schinifolium精油 (ZSEO) 的微封装.
- 为了增强ZSEO的稳定性和实现控制释放使用BCNFs/WPI复合物修改了 cinnamaldehyde (CA).
- 研究开发的微囊的相互作用和特性.
主要方法:
- 喷雾干燥技术用于制备微囊.
- 优化涉及不同的BCNF/WPI复合物度和比率以及CA含量.
- 描述包括物理性质分析,光谱学,分子动力学模拟和体外消化研究.
主要成果:
- 使用1.0重%的BCNFs/WPI (1:7比) 和0.7重%的CA形成了最佳的微囊,实现了90.81%的封装效率.
- 光谱和模拟证实了AC与矩阵组件之间的键和静电相互作用,增加了结合能.
- 经过修改的微囊在水性和油性介质中释放延迟,并在体外消化过程中增强稳定性.
结论:
- 使用CA修改的BCNFs/WPI复合体进行ZSEO的微封装是改善稳定性和受控释放的有效策略.
- 丁甲在增强微囊系统内的物理性质和相互作用方面发挥着至关重要的作用.
- 这种方法为开发稳定和功能化的精油输送系统提供了宝贵的见解.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...